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Abstract 
The effects of interleukin-13 (IL-13) and interleukin-4 (IL-4) on cellular functions were shown to be quite similar. We provide evidence that in 
monocytes as well as in T lymnhocytes both IL-4 and IL-13 activate the same recentlv identified transcrintion factor NF-IL4 which binds to the specific 
responsive lement IG4RE. In addition, we show that a nuclear factor activated by interferon-y also interacts with the IL-4RE. It differs from NkIL4 
in the electrophoretic mobility of the complex with DNA, in its DNA-binding speciticity and in the proteins interacting with the DNA sequence. 
Sensitivity against various enzyme inhibitors suggests that components of the signal transduction pathway are shared by all three cytokines. 
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1. Introduction 
Interleukin-4 (IL-4) is an important immunoregula- 
tory cytokine which has pleiotropic effects on a variety 
of cell types [l]. It is predominantly secreted by activated 
Th2-‘like’ cells [2] and by mast cells [3] and is one of the 
major promoters of the ‘ThZtype immune response. 
IL-4 stimulates proliferation of B lymphocytes and pro- 
motes the production of certain immunoglobulin 
isotypes such as IgG4 and IgE in humans [l]. Another 
characteristic activity of IL-4 is the induction of the low 
affinity receptor for IgE (FaRIUCD23) in various cell 
types such as B lymphocytes [4], monocytes [5] and 
T cells [6]. These effects are initiated by the binding of 
IL-4 to a specific surface receptor (IL4R) consisting of 
a 140 kDa polypeptide chain [7] which can be associated 
with a common y chain (r,) shared with other cytokine 
receptors such as IL-2 and IL-7 receptors [8-lo]. The 
signalling pathway connecting the IL4R with the activa- 
tion of gene transcription has remained elusive so far. 
Recently, we identified an IL-4 responsive lement in the 
promoter regions of the CD23b and IE genes (IL4RE) 
which is specifically bound by the novel IL-4-induced 
transcription factor NF-IL4 [ 111. NF-IL4 is posttransla- 
tionally activated within a few minutes after IL-4 stimu- 
lation and its binding to IL4RE represents the final step 
of the IL-4 signalling pathway. Lately, another cytokine, 
interleukin-13 (IL-13) has been described which has ef- 
fects quite similar to IL-4 on the expression of various 
*Corresponding author. Fax: (49) (89) 5160 2236. 
genes in a number of different cell types [12,13]. It has 
been shown to induce IgG4 and IgE synthesis by human 
B cells, to promote CD23 expression in B cells and mon- 
ocytes and to inhibit IL-6 synthesis [12-161. However, it 
differs from IL-4 by its inability to activate T lympho- 
cytes [14,17]. Studies with a mutant form of the human 
IL-4 and with a transfected IL-4R ligand binding protein 
suggested that both the IL4R and the IL-13R share a 
receptor subunit involved in signal transduction [17. Ac- 
cording to recent reports this additional receptor chain 
might be identical with the common cytokine receptor y 
chain “/c [8,9]. In this study we show that stimulation of 
monocytic cells and T cells with IL-l 3 activates anuclear 
binding protein which binds to the same IL-4-responsive 
element IL-4RE as NF-IL4 We provide evidence, that 
both binding factors are identical. (1) The complexes 
formed by both factors have identical electrophoretic 
mobility; (2) complex formation by both factors is 
equally sensitive to competition by different binding mo- 
tifs; (3) crosslinking of the IL4RE with the binding pro- 
teins after complex formation revealed that the co- 
valently bound proteins derived from both factors have 
the same relative molecular mass. 
Whereas IL-4 is the principal promoter of the ‘Th2- 
type’ immune responses the ‘Thl-type’ response is 
guided by interferon-y (IFN-y) [2]. Depending on the 
cell type, the effects of IFN-y on gene expression are 
either antagonistic or analogous to the activity of IL-4 
[4,18,19]. Here we show that IFN-y activates a nuclear 
factor which binds to the IL4RE. However, the mobility 
of the resulting complex in EMSA is different from that 
of the NF-IL4/IL_4RE complex. In addition, we provide 
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evidence for similarities between the signal transduction 
activated by IL-4 or IL-13 and the signalling pathway 
initiated by IFN-y. 
BrdU) oligonucleotides (Eurogentec, Seraing, Belgium) and labeling by 
incorporation of [a-?jdATP using Klenow polymerase (see section 2.3): 
5’-AGCBBBCBBAGAAATTCAAGCT-3’ 
3’-TCGAAAGAABCBBBAAGBTCGA-5’. 
2. Materials and methods 
2.1. Reagents 
Human recombinant IL-4 (rIL-4) was prepared from the supernatant 
of CHO cells which had been stably transfected with the IL-4 gene in 
collaboration with Boehringer-Mannheim (Penzberg, Germany). Re- 
combinant human IFN-I (rIFN-r) was obtained from Biogen (Cam- 
bridge, MA, USA). Recombinant human IL-13 (rIL-13) was prepared 
as described [12]. The following enzyme inhibitors were used: stauro- 
sporine as a broad spectrum kinase inhibitor, genistein as a specific 
inhibitor of tyrosine kinase, calyculin A as inhibitor of serine/thrwnine 
phosphatases, and H7 as inhibitor of protein kinase C. All inhibitors 
were purchased from Calbiochem (Bad Soden, Germany). The mono- 
clonal anti-phosphotyrosine antibody IG2 was obtained from Amer- 
sham (Braunschweig, Germany). 
2.2. Cells 
Mononuclear blood cells (PBMC) were prepared by FicoWI-Iypaque 
density centrifugation of heparin&ed venous blood samples. T lympho- 
cytes were isolated from PBMC at >99% purity by a direct monoclonal 
antibody rosetting technique using bovine erythrocytes coated with a 
monoclonal CD2 antibody essentially as described [20]. Monocytes 
were enriched by removal of T and B lymphocytes from PBMC using 
the same technique. The monocytic cell line U937 was obtained from 
the American Type Tissue Collection. Cells were cultured in RPM1 
1640 medium containing 5% fetal calf serum, 1 mM glutamine, 100 
U/ml penicillin and 100 &ml streptomycin. 
2.3. Electrophoretic mobility shift assay (EMSA) 
For complex formation with nuclear binding factors the following 
IL-QRE containing DNA sequences were synthesized, the IL-4REs 
are underlined: (a) from the CD23b promoter 111,211 5’-GGTGAA- 
‘MTCTAAG~GG-3’; and @) the-interferon-y responsive region 
(GRR) from the promoter of the Fey receptor I (FcyRI, CD64) [22] 
S-AGCATGT’ITCAAGGATTTGAGATGTATITCCCAGAAAA- 
G-3’. In addition, an oligonuclwtide containing the IFN-7 activation 
site (GAS) as a binding motif for the IFN-y-induced activation factor 
(GAF) was prepared for use in control experiments: S-AT- 
TACTCTAAA3’ (sequence taken from [23]). The oligonucleotides 
were end-labeled. &ng the Klenow klymerase _ (Boehringer 
Mannheim, Germany) together with [a--“P]dATP (Amersham, 3000 
Ci/mmol) and the three other dNTPs in unlabeled form. Nuclear ex- 
tracts w&e prepared according to Dignam et al. [24]. The nuclear 
extracts (3-5 pg) were incubated on ice for 30 min with the 32P-labeled 
oligonuclwtide in 20 ~1 of binding buffer consisting of 2 mM HEPES 
@H 7.9), 100 mM KCl, 10 mM Tris-HCl @H7..5), 5 mM dithiothreitol, 
1.5 mM EDTA, 15% glycerol, 1 mg/ml BSA, 15 &ml aprotinin, 
0.5 mM PMSF and 2c(g of the carrier polymer poly(dI-dC) (Pharmacia, 
Freiburg, Germany). The DNA-protein complexes were separated in 
a 4% polyacrylamide gel in 0.5 x TBE which was then exposed to an 
X-ray fihn (Kodak XOMAT AR). Competition of complex formation 
was performed with the ImRE-containing sequences from the CD23b- 
and-CD64-promoter (see above). In addition, the following two mu- 
tants M-l and M-2 of the CD23b-IL-4RE were used, in which single 
base pair exchanges were introduced known to be e&ential for <F- 
&&binding (the mutated positions are underlined): M-l, 
5’-GGTGAAT’ITCTAAAAAA GG-3’; M-2, 5’GGTGAATTICTA 
GGAAAGG-3’. The nu&ar extracts were incubated in a DNA binding 
& containing a 20-fold molar excess of unlabeled double stranded 
competitor oligonucleotides for 15 min on ice. After addition of the 
“P-labeled IL-QRE-containing sequence of the CD64 promoter the 
incubation was continued for 30 min. The complexes were then sepa- 
rated as described above. 
2.4. WV cross-linking 
For cross-linking experiments the following double stranded ol- 
igonucleotide was generated by annealing two BrdU-containing (B = 
Nuclear extracts (10 pg of protein) were incubated with 50 fmol of 
the BrdU-substituted oligonucleotide for 20 min at 2O”C, then hadi- 
ated on ice with UV light (305 mn) at a distance of 5 cm for 20 min. 
The reaction mixture was separated on a 4% polyacrylamide gel. The 
gel was then irradiated by UV light (305 mn) at a distance of 5 cm for 
20 min on ice before exposing to an X-ray 6hn for 3 h. The detected 
radioactive bands were excised as indicated in Fig. 4, electroeluted and 
separated on a denaturing 10% SDS polyacrylamide gel which was then 
exposed to an X-ray lihn. 
3. Results and discussion 
3.1. Both IL-13 and IL-4 activate the transcription factor 
NF-IL.4 
IL-4 and IL- 13 have similar biological effects on vari- 
ous cell types and use cellular receptors which suppos- 
edly share a receptor subunit. These findings strongly 
suggest that IL-4 and IL-13 initiate the same signalling 
cascade resulting in the activation of the IL+dependent 
transcription factor NF-IL4. In order to prove this hy- 
pothesis nuclear extracts were prepared from U937 cells 
stimulated either with 100 @ml of rIL-13 or 400 U/ml 
of rIL-4 for 15 min and then incubated with the radiola- 
beled IL4RE from the CD23b promoter. Both types of 
nuclear extracts formed a complex with the same mobil- 
ity in EMSA (Fig. la, lanes 2 and 3). Recent reports 
indicated that IL-4 and IL-13 differ in their effects on a 
a) u937 oelk 
NF-IL4 + 
Fig. 1. Induction of a nuclear bmding factor by IL13 forming a com- 
plex with IL-4RE and displaying the same electrophoretic mobility as 
the NF-IL4/&4RE complex. (a) induction in U937 cells; (b) induction 
in purified blood T lymphocytes. 2 x lo7 cells were incubated for 15 min 
without or with either 100 &ml rIL-13 or 400 U/ml rIL-4. Nuclear 
extracts were then incubated with the “P-labeled IL-4RE from the 
CD23b promoter and analysed in EMSA. The arrow indicates the band 
representing the NF-IL4 complex. 
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Fig. 2. (a) Induction of a nuclear bmding factor by IFN-r in U937 cells 
which forms a complex with IL-4RE. 2 x 10’ U937 cells were incubated 
for 15 min without or with either 1000 U/ml rIFN-r or 400 U/ml rIL-4. 
Nuclear extracts were incubated with the 32P-labeled IL-4RE from the 
CD23b promoter and analysed in EMSA. (b) Presence of a nuclear 
factor binding to IL4RE in freshly isolated blood monocytes. Nuclear 
extracts were prepared from enriched blood monocytes after incubation 
for 1.5 min with or without 400 U/ml rIL4 or 100 @ml rIL-13 or 1000 
U/ml rIFN-y, incubated with the “P-labeled IL-QRE-containing se- 
quence from the CD64 promoter and analysed in EMSA. The single 
arrow indicates the band representing the complex formed with NF- 
IL4, the double arrow shows the position of the IFN-y-dependent 
complex. 
number of T cell functions [14,171. In contrast to IL-4, 
IL13 is not capable to promote growth of T cell clones 
or to induce expression of CD&z on CD4’ T cell clones. 
These findings were taken as an indication for the lack 
of functional IL-13 receptors on T lymphocytes [17]. 
Hence, it was of particular interest to find out whether 
these cytokines differ also in their capability to activate 
NF-IL4 in T lymphocytes. To this end, highly purified 
blood T cells were treated with rIL-4 and rIL-13 for 
15 min followed by analysis of the nuclear extracts in 
EMSA. As shown in Fig. lb, lanes 2 and 3, both cytok- 
ines were able to activate NF-IL4 in T cells. Therefore, 
the diverse functional effects of IL-4 and IL- 13 on T cells 
cannot be explained by a different capacity to induce the 
transcription factor NF-IL4 in T ceils. Above all, our 
finding is at variance with the notion that T cells do not 
express functional IL-13 receptors. It is still possible that 
the induction of T cell functions by IL-4 require yet 
unknown cooperative factors which IL-1 3 is unable to 
activate in T cells. 
3.2. The IL-4- and IL-13-induced NF-IL4 shares a DNA 
binding motif with an IFN-yactivatednuclear binding 
factor 
IFN-y has been shown to activate a transcription fac- 
tor containing the p91 protein [25], which binds to the 
IFN-y response region (GRR) in the promoter of the 
FcyRI (CD64) gene [26]. This region contains at the 
3’ end a sequence which is homologous to the IL-4RE 
and which is recognized by NF-IL4 (unpublished obser- 
vation). During our analysis of gene activation by Thl- 
and Th2-derived cytokines we realized that IFN-y in- 
duces a nuclear binding factor in U937 cells which forms 
a complex with the IL-4RE derived from the CD23b 
promoter as well as with the IL-4RE from the CD64 
promoter. In EMSA, this complex has a somewhat faster 
mobility when compared with the NF-IL4/&4RE com- 
plex (Fig. 2a, lanes 2 and 3). In the course of preparing 
this manuscript we became aware of a paper reporting 
similar results for THP-1 cells [27’J. When we analysed 
freshly prepared blood monocytes which had not been 
intentionally treated with cytokines we frequently ob- 
served a nuclear factor forming a complex with the IL- 
4RE of the CD23b promoter. In EMSA this complex 
migrated with a mobility identical to that obtained for 
the complex after IFN-y treatment (Fig. 2b, lanes 1, 3 
and 5). When such cells were treated for 15 min with 
rIL-4 the lower band corresponding to the IFN-y-in- 
duced binding factor disappeared in EMSA and predom- 
inantly NF-IL4 was extracted from the nuclei (Fig. 2b, 
lane 2). The same eff’ect was seen when fresh monocytes 
were treated with rIL-13 (Fig. 2b, lane 4). Incubation of 
1 2 3 4 5 6 7 6 9 10 11 12 13 
1 2 3 4 5 6 7 6 9 10 11 12 13 
Fig. 3. Competition of complex formation between nuclear factors 
induced by IL-4, IL13 or IFN-r and ILARE analysed by EMSA. 
Nuclear extracts from U937 cells stimulated by the various cytokines 
were prepared as described in the legends to Figs. 1 and 2 and incubated 
with a 20-fold molar excess of different competitor DNAS as indicated 
on top of the gel before adding the ‘?-labeled IL-4RE! of the CD64 
promoter. Following EMSA the exposed X-ray film was scanned on a 
densitometer. The r lative intensity of the bands corresponding to spe- 
cific complexes is shown as a diagramm. For each stimulation (lanes 
1,6 and 11) the lanes without competitor were set as 100%. 
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IL-4 IL-13 IFN-y 
1 2 3 4 5 
Fig. 4. UV-cross-linking of a BrdU-substituted oligonucleotide cany- 
ing the IL-4RE of the CD23b promoter with different nuclear extracts. 
The extracts of U937 cells stimulated without (-) or with IL-4, IL-13 
or IFN-y were crosslinked and separated on a 4% EMSA-ye1 (upper 
gel). The specitic complexes were excixed, eluted and separated on a 
10% SDS-polyacrylamide gel (lanes 24), which was then exposed to 
an X-ray film (lower gel). M (lanes 1 and 5) indicates a “C-labeled 
molecular weight standard. The single and double arrows mark the 
separated proteins covalently bound to the labeled DNA. 
., 
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monocytes for 15 min with rIFN-y resulted in an ampli- 
fication of the lower band. The reason for this constitu- 
tive factor expression in freshly isolated blood mon- 
ocytes remains to be elucidated. These findings suggest 
that under certain experimental conditions, particularly 
in the absence of a continuous IFN-7 stimulus, the IFN- 
y-induced binding factor can be displaced from its DNA 
motif by newly induced NF-IL4. Taken together, these 
data indicate that different nuclear binding factors acti- 
vated by diverse cytokines can share a DNA binding 
motif and may thus compete with each other for DNA 
sequences or for DNA-binding protein components. 
This phenomenon may contribute to the antagonistic 
regulation of gene activation by certain cytokines. How- 
ever, this hypothesis has to be proven by analyzing bind- 
ing of purified nuclear factors. 
3.3. Comparative analysis of the nuclear binding factors 
The finding that IL-4 and IL- 13 induce nuclear factors 
forming complexes with IL4RE of corresponding elec- 
trophoretic mobility suggests that the factors are identi- 
cal. To provide additional evidence for that a series of 
comparative analyses was performed. These experiments 
included a more detailed characterization of the IFN- 
y-induced IL-4RE-binding nuclear factor. First, the 
binding specificity of the factors was tested by competing 
the complex formation with the radiolabeled IL-4RE 
- from the CD64 promoter by various informative ol- 
igonucleotides. As shown in Fig. 3, the two CD23b and 
CD64 promoter motifs were similarly efficient in com- 
peting the binding of the radiolabeled CD64-IL-4RE to 
both the IL-4- and IL-l 3-induced factors. This indicates 
that the factors bind to the two motifs with comparable 
afhnity. In contrast, the IFN-y-induced factor appeared 
to have a much stronger affinity to the CD64-IL-4RE 
than to the CD23b-IL-4RE. Furthermore, complex for- 
mation of the IL-4- and IL-13-induced factors was 
equally resistant o competition by the two oligonucleo- 
tides M-l and M-2 carrying point mutations within the 
IL4RE. In a second set of experiments it was found that 
the DNA-binding proteins derived from both the IL-4- 
and IL-13-induced nuclear factors have the same size in 
a denaturing SDS gel after cross-linking to the IL4RE 
(Fig. 4, lanes 2 and 3). One major band appeared be- 
tween 110 and 130 kDa (single arrow in Fig. 4). An 
additional smaller band of about 50 kDa was detectable 
in both lanes (double arrow in Fig. 4). When the IFN-)I- 
induced nuclear factor was analysed by the same method 
only this band of about 50 kDa was found. IFN-a has 
been shown to induce a nuclear factor binding to the 
interferon stimulated response lement (ISRE). This fac- 
tor is composed of at least four proteins ~113, p91, ~84 
and p48 with ~48 as the DNA-binding component [28]. 
On the other hand, IFN-y activates a nuclear factor 
binding to the y-interferon activation site (GAS) where 
the p91 was shown to be the DNA-binding constituent. 
However, the IFN-y-activated protein directly interact- 
ing with the IL-4RE has not been identified so far. Ac- 
IL- 4 IL-13 1FN-y 
r-inn 
anti-PTyr - - + - + - + 
._ 
NF-IL4 + 
NF (IFN- r)+ 
1234567 
Fig. 5. Reduction of complex formation between IL4 and IL-13- 
induced nuclear binding factors and the 3rP-labeled IL-4RE of the 
CD23b promoter by a monoclonal anti-phosphotyrosine antibody 
(anti-PTyr). As a control, reduction of complex formation between an 
IFN-y-induced nuclear binding factor and the “P-labeled GAS se- 
quence by the anti-phosphotyrosine antibody is shown. 1.8 pug of the 
anti-PTyr were added to 40 pl of nuclear extract solution in binding 
buffer for 60 min. Then the 32P-labelled oligonucleotide was added for 
a further 30 min followed by EMSA. The single arrow indicates the 
band representing the complex formed with NF-IL4, the double arrow 
shows the position of the IFN-y-dependent complex. 
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Fig. 6. Effect of various enzyme inhibitors on the activation of nuclear binding factors by (a) IL-4, (b) IL-13 and (c) IFN-I. Cells were preincubated 
with the enzyme inhibitors as described in section 3 and then stimulated for I5 mitt with the cytokines. Nuclear extracts were incubated with the 
“P-labeled IL-4RE of the CD23b promoter (a) and (b) or with the radiolabeled GRR sequence (c) and then analysed in EMSA. The single arrow 
indicates the band representing the complex formed with NF-IL4, the double arrow shows the position of the IFN-y-dependent complex. 
cording to our data it could be the p48. This view is 
supported by the finding of a deficient IFN-y-signalling 
in a cell line expressing a truncated p48 [29]. This p48 
seems to be a constitutive cellular protein which is re- 
cruited to DNA-binding complexes after IFN stimula- 
tion. Based on our observation that the IL-4- and IL-13- 
activated nuclear factors contain a DNA-binding com- 
ponent of a corresponding size one might speculate that 
p48 is also involved in the binding of NF-IL4 to IL4RE. 
The major DNA-binding element of NF-IL4, however, 
has a size between 110 and 130 kDa. It is not yet clear 
whether it corresponds to the ~113, another component 
of the IFN-activated nuclear factor family. Since the 
IFN-y-induced transcription factor is activated by a 
phosphorylation at Tyr7” of the p91 component [28] it 
was of interest to determine whether also the IL4- and 
IL-13- activated nuclear binding factors are 
phosphorylated on tyrosine. For this, in a third set of 
experiments the nuclear extracts obtained from IL-4- or 
IL-13-treated cells were incubated with a monoclonal 
anti-phosphotyrosine antibody before adding the 32P- 
labelled IL4RE motif for another 30 min. By this treat- 
ment, the complex formation by both factors was signif- 
icantly reduced when compared with the untreated con- 
trol (Fig. 5, lanes 2-5). The efficiency of the antibody was 
controlled by its effect on the complex formation be- 
tween the GAS sequence and the IFN-y-induced nuclear 
factor GAF which has been reported to be tyrosine 
phosphorylated [28]. The finding that the complex for- 
mation was inhibited by the anti-phosphotyrosine anti- 
body and did not result in a supershift indicates that the 
phosphorylated tyrosine is related to the DNA binding 
site of NF-IL4. Taken together, these data provide 
strong evidence for the identity of the nuclear binding 
factors activated by IL-4 and IL-13. 
3.4. Similar enzymes are involved in signailing by IL-4, 
IL-13 and IFN-y 
Little is known about the signal transduction pathway 
after binding of IL-4 or IL- 13 to their membrane recep- 
tors. We had previously shown that classical second mes- 
sengers such as inositol phospholipid metabolites, ele- 
vated cytoplasmic Ca’+, protein kinase C or CAMP are 
not involved in the activation of the IL-4-dependent 
transcription factor NF-IL4 [l 11. In order to test the 
contribution of kinases and phosphatases to the sig- 
nalling cascade resulting in the activation of NF-IL4 
U937 cells were treated with different enzyme inhibitors 
prior to stimulation with IL-4 or IL-13. Incubation of 
cells with the broadly reacting kinase inhibitor stauro- 
sporine at a concentration of 1 ,uM for 1 h blocked both 
the IL-4- and IL-13-dependent NF-IL4 activation (Fig. 
6a, lane 2, and Fig. 6b, lane 2). Genistein, a specific 
inhibitor of tyrosine kinases, had little effect when ap- 
plied at 100 pg/ml for 1 h, however, treatment of cells for 
16 h with the same concentration of genistein resulted in 
complete inhibition of complex formation (lanes 3 and 
4 in Fig. 6a and 6b). When calyculin A, a specific inhib- 
itor of serine/threonine phosphatases, was applied to the 
cells for 1 h at a concentration of 10 nM, activation of 
NF-IL4 by the two cytokines was prevented (Fig. 6a, 
lane 5 and Fig. 6b, lane 5), whereas the inhibitor of 
protein kinase C, H7, at 3 ,uM for 1 h was unable to 
interfere with NF-IL4-induction (Fig. 6a, lane 6 and Fig. 
6b, lane 6). The finding that activation of NF-IL4 is 
impeded by an inhibitor of tyrosine kinases is consistent 
with previous reports showing that a tyrosine kinase is 
involved in the IL-4 signal transduction pathway [27,30]. 
The involvement of serine/threonine phosphatases in the 
IL-4/IL-13 signalling is a new observation. The identity 
of inhibition patterns is in favour of a common pathway 
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for both IL-4- and IL-1 3-signalling. This view is sup- 
ported by the notion that both the receptors for IL-4 and 
IL-13 share an afsnity converting subunit that is critical 
for cellular signal transduction [17]. In a parallel set of 
experiments the IFN-y signalling pathway which results 
in the activation of a nuclear factor binding to IL-4RE 
was analysed with regard to blockade by enzyme inhib- 
itors. As shown in Fig. 6c, activation of this nuclear 
factor was sensitive to the same enzyme inhibitors as the 
induction of NF-IU. This similarity of inhibition pat- 
terns suggests that the IL&IL-13-induced signalling be- 
longs to a category of signal transduction pathways 
which has been described for the interferon-induced acti- 
vation of transcription factors and for which the ‘direct 
effector’ model has been proposed [31]. 
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